Alkermes Receives Refusal to File Letter From FDA for ALKS 5461
Alkermes plc announced that it received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461, a once-daily,…
Read More...
Read More...
